Can rybrevant be used for exon 20 insertions?

Rybrevant and Exon 20 Insertions: What You Need to Know

Rybrevant (amivantamab-vmjw) is a medication approved by the FDA for the treatment of certain types of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations [1].

What are EGFR exon 20 insertions?

EGFR exon 20 insertions are a specific type of mutation in the EGFR gene that can lead to NSCLC. This mutation occurs when a section of genetic material is inserted into the EGFR gene, causing it to become overactive [2].

Is Rybrevant effective for exon 20 insertions?

According to clinical trials, Rybrevant has shown significant efficacy in treating patients with EGFR exon 20 insertion mutations. The drug has demonstrated a high overall response rate, durable response, and manageable adverse events [3].

Why is Rybrevant used for exon 20 insertions?

Rybrevant works by binding to the EGFR receptor and inhibiting its activity, which helps to slow down the growth and spread of cancer cells. The drug's mechanism of action makes it an effective treatment for exon 20 insertion mutations, which are associated with EGFR overactivity [4].

Who makes Rybrevant?

Rybrevant is developed by Janssen Biotech, Inc. under a collaboration with Astellas Pharma Inc. [5].

When does the patent expire?

As per [DrugPatentWatch.com], the patent for Rybrevant is set to expire in 2035 [6].